{
    "patient": {
        "Name": "Heather Ellison",
        "DateOfBirth": "1952-11-07",
        "Sex": "Male",
        "Diagnosis": "Pancreatic neuroendocrine tumors",
        "BodyPart": "Pancreatic",
        "Physician": "Dr. Hector Flores",
        "TreatingInstitution": "Jackson, Herrera and Anderson"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Pancreatic",
            "CollectedDate": "2023-12-09",
            "ReceivedDate": "2023-12-12",
            "TumorPercentage": "72%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-12-13",
            "ReceivedDate": "2023-12-16"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "BLM",
                "DNA Alteration": "c.2207_2212delinsTAGATTC",
                "GeneMutation": "p.Y736fs*4 Spliceregionvariant-GOF",
                "VariantAlleleFraction": "19.6%"
            },
            {
                "Gene": "NCSTN",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A572G Stopgain-LOF",
                "VariantAlleleFraction": "23.45%"
            },
            {
                "Gene": "NCSTN",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A572G Spliceregionvariant-LOF",
                "VariantAlleleFraction": "25.26%"
            },
            {
                "Gene": "FLT3",
                "DNA Alteration": "c.1775T>G",
                "GeneMutation": "p.V592A Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "4.84%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "MYOD1",
                "DNA Alteration": "c.365T>G",
                "GeneMutation": "p.V592G Frameshift-LOF",
                "VariantAlleleFraction": "10.31%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "SIX1",
            "FGFR3"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "31 m/Mb",
            "Tmbpercentile": "49%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "Stable"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "NRAS",
                "DNA Alteration": "c.181C>A",
                "GeneMutation": "p.Q61E Stopgain-LOF",
                "VariantAlleleFraction": "15.34%"
            },
            {
                "Gene": "FGFR3",
                "DNA Alteration": "c.1118A>G",
                "GeneMutation": "p.R248C Stopgain-LOF",
                "VariantAlleleFraction": "1.41%"
            },
            {
                "Gene": "RNF43",
                "DNA Alteration": "c.954G>T",
                "GeneMutation": "p.E318D Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "11.09%"
            },
            {
                "Gene": "PDGFRB",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.T681I Nonsense-GOF",
                "VariantAlleleFraction": "3.01%"
            },
            {
                "Gene": "HRAS",
                "DNA Alteration": "c.35G>T",
                "GeneMutation": "p.G12D Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "2.79%"
            },
            {
                "Gene": "PIK3CA",
                "DNA Alteration": "c.1635G>C",
                "GeneMutation": "p.C420R Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "7.25%"
            },
            {
                "Gene": "PDGFRA",
                "DNA Alteration": "c.1153_1154delinsTC",
                "GeneMutation": "p.K385X Nonsense-GOF",
                "VariantAlleleFraction": "7.65%"
            },
            {
                "Gene": "DPYD",
                "DNA Alteration": "c.2846A>T",
                "GeneMutation": "p.Y186C Stopgain-LOF",
                "VariantAlleleFraction": "6.81%"
            },
            {
                "Gene": "CHEK2",
                "DNA Alteration": "c.1283C>T",
                "GeneMutation": "p.I157T Spliceregionvariant-GOF",
                "VariantAlleleFraction": "6.0%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "NCSTN",
        "MYD88",
        "SDHB"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "BLM",
                "DNA Alteration": "c.2207_2212delinsTAGATTC",
                "GeneMutation": "p.Y736fs*4 Spliceregionvariant-GOF",
                "description": "TP53 encodes a protein that is a transcription factor that regulates the expression of genes involved in cell cycle arrest, apoptosis, and DNA repair. TP53 is a tumor suppressor gene that is mutated in many cancers. Mutations in TP53 are associated with cancer progression.",
                "VariantAlleleFraction": "19.6%"
            },
            {
                "Gene": "NCSTN",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A572G Stopgain-LOF",
                "description": "NFE2L2 acts as a transcription factor for proteins that contain an antioxidant response element (ARE) within their promoter sequence. Genes that contain ARE are involved in injury and inflammation response. Activating mutations and overexpression of NFE2L2 are associated with cancer progression.",
                "VariantAlleleFraction": "23.45%"
            },
            {
                "Gene": "NCSTN",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A572G Spliceregionvariant-LOF",
                "description": "ARID2 encodes a protein that is a subunit of the SWI/SNF chromatin remodeling complex SWI/SNF-B or PBAF. This complex functions in ligand-dependent transcriptional activation. Loss of function mutations and copy number loss of ARID2 are associated with cancer progression.",
                "VariantAlleleFraction": "25.26%"
            },
            {
                "Gene": "FLT3",
                "DNA Alteration": "c.1775T>G",
                "GeneMutation": "p.V592A Missensevariant(exon2)-GOF",
                "description": "TP53 encodes a protein that is a transcription factor that regulates the expression of genes involved in cell cycle arrest, apoptosis, and DNA repair. TP53 is a tumor suppressor gene that is mutated in many cancers. Mutations in TP53 are associated with cancer progression.",
                "VariantAlleleFraction": "4.84%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "MYOD1",
                "DNA Alteration": "c.365T>G",
                "GeneMutation": "p.V592G Frameshift-LOF",
                "description": "STK11 (LKB1) encodes an enzyme in the serine/threonine kinase family that is responsible for maintaining energy metabolism and cellular polarization through the activation of AMP-activated protein kinase and other members of the AMPK family. The enzyme also acts as a tumor suppressor by regulating cell growth. Loss of function mutations, copy number loss, epigenetic variation, and underexpression of STK11 are associated with cancer progression.",
                "VariantAlleleFraction": "10.31%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-12-08"
    },
    "other": {
        "ReportId": "4816",
        "ReportDate": "2023-12-13",
        "SignedBy": "Hector Flores",
        "Supervisor": "Dr. Ashley Evans"
    }
}